NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
Clinical Trials
7 trialsNCT06063746 2026-01-08
Compassionate Use of Vidutolimod
Regeneron Pharmaceuticals
No longer available
NCT04489433 2025-12-18
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
Novartis
No longer available
NCT06590480 2025-12-18
RPL-EAP-001
Replimune Inc.
No longer available
NCT06132191 2025-11-20
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Regeneron Pharmaceuticals
Approved for marketing
NCT05398640 2025-06-17
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
Iovance Biotherapeutics, Inc.
Available
NCT03593499 2025-05-31
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
Biogen
No longer available